No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

PenRad Announces PenAlert

A New Paradigm In Diagnostic Imaging Reports In Patient's Language And Terminology

Editor: What To Know

  • PenRad, the Radiologists preferred mammography and LDCT reporting and tracking system, has created PenAlert in direct response by expanding the footprint to all diagnostic imaging.
  • The patient exam letter describes findings and concerns, or normal results can be communicated as well, all in patient terminology.
  • This enhances patient satisfaction, tracking patients and findings to resolution, and assists the referring physician with direct patient result notification.

As various regulations evolve and malpractice rates increase, imaging providers need to take a proactive approach to notify patients directly of any significant abnormality or normal result. Pennsylvania (PA112) already has set a precedent, adding burden and liability concerns for radiologists and referring physicians.

PenRad, the Radiologists preferred mammography and LDCT reporting and tracking system, has created PenAlert in direct response by expanding the footprint to all diagnostic imaging. PenAlert automates patient notification with zero change to Radiologist workflow, while aiding in practice liability management. This enhances patient satisfaction, tracking patients and findings to resolution, and assists the referring physician with direct patient result notification. Currently, PenRad’s technology provides these benefits to more than 10,000,000 exams per year, in mammography alone.  PenAlert represents a move to provide these benefits to all diagnostic imaging and millions of additional exams.

PenAlert uses machine learning intelligence to extract key findings from the radiologist’s narrative report and catalogs the exam and findings. The patient exam letter describes findings and concerns, or normal results can be communicated as well, all in patient terminology. This automation inserts referring physician contact info, sub-specialty care specialists (if applicable), future recommended imaging, and more. All this detail is in the patient’s preferred language, with automated delivery via; email, mail, an existing Portal or our PenXpress patient portal.

Other features include recall letters, management reports, analytics for findings and outcomes. PenAlert facilitates compliance with key CMS quality payment program requirements and increases the opportunity to report compliance and best practices with Medicare’s Merit-based Incentive Payment System (MIPS).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy